| Market Cap | 43.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -78.62M | Forward P/E | -1.32 | EPS next Y | - | 50D Avg Chg | 15.00% |
| Sales | 338k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -32.00% |
| Dividend | N/A | Price/Book | 0.39 | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | 2.00 | Quick Ratio | 3.82 | Shares Outstanding | 4.58M | 52W Low Chg | 68.00% |
| Insider Own | 21.01% | ROA | -33.02% | Shares Float | 2.92M | Beta | 2.77 |
| Inst Own | 22.71% | ROE | -111.07% | Shares Shorted/Prior | 69.89K/111.73K | Price | 0.99 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 70,845 | Target Price | - |
| Oper. Margin | -18,017.46% | Earnings Date | Aug 13 | Volume | 34,635 | Change | 5.81% |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Chardan Capital | Buy | Aug 15, 23 |
| Chardan Capital | Buy | May 11, 23 |
| Morgan Stanley | Equal-Weight | Mar 24, 23 |
| Chardan Capital | Buy | Mar 23, 23 |
| Chardan Capital | Buy | Jan 30, 23 |
| Morgan Stanley | Equal-Weight | Jan 27, 23 |
| JP Morgan | Neutral | Dec 16, 22 |
| Morgan Stanley | Equal-Weight | Oct 7, 22 |
| B of A Securities | Buy | Sep 29, 22 |